1. Home
  2. VRTX vs ADI Comparison

VRTX vs ADI Comparison

Compare VRTX & ADI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • ADI
  • Stock Information
  • Founded
  • VRTX 1989
  • ADI 1965
  • Country
  • VRTX United States
  • ADI United States
  • Employees
  • VRTX N/A
  • ADI N/A
  • Industry
  • VRTX EDP Services
  • ADI Semiconductors
  • Sector
  • VRTX Technology
  • ADI Technology
  • Exchange
  • VRTX Nasdaq
  • ADI Nasdaq
  • Market Cap
  • VRTX 104.8B
  • ADI 105.1B
  • IPO Year
  • VRTX 1991
  • ADI 1972
  • Fundamental
  • Price
  • VRTX $484.24
  • ADI $238.91
  • Analyst Decision
  • VRTX Buy
  • ADI Buy
  • Analyst Count
  • VRTX 25
  • ADI 23
  • Target Price
  • VRTX $505.61
  • ADI $253.59
  • AVG Volume (30 Days)
  • VRTX 1.5M
  • ADI 4.2M
  • Earning Date
  • VRTX 02-10-2025
  • ADI 02-19-2025
  • Dividend Yield
  • VRTX N/A
  • ADI 1.66%
  • EPS Growth
  • VRTX N/A
  • ADI N/A
  • EPS
  • VRTX N/A
  • ADI 3.13
  • Revenue
  • VRTX $11,020,100,000.00
  • ADI $9,337,627,000.00
  • Revenue This Year
  • VRTX $9.62
  • ADI $8.92
  • Revenue Next Year
  • VRTX $9.25
  • ADI $13.56
  • P/E Ratio
  • VRTX N/A
  • ADI $76.14
  • Revenue Growth
  • VRTX 11.66
  • ADI N/A
  • 52 Week Low
  • VRTX $377.85
  • ADI $182.57
  • 52 Week High
  • VRTX $519.88
  • ADI $247.10
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 65.58
  • ADI 68.52
  • Support Level
  • VRTX $451.99
  • ADI $200.80
  • Resistance Level
  • VRTX $469.55
  • ADI $247.10
  • Average True Range (ATR)
  • VRTX 11.70
  • ADI 6.15
  • MACD
  • VRTX 0.97
  • ADI 4.17
  • Stochastic Oscillator
  • VRTX 83.48
  • ADI 82.31

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About ADI Analog Devices Inc.

Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.

Share on Social Networks: